2 terminated, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Matthias Griese: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD) Hydroxychloroquine sulfate, Placebo - Interstitial Lung Disease, Diffuse Parenchymal Lung Disease | Phase 2 | Terminated | Matthias Griese | 35 | 2015-08-21 | 2025-12-03 |
| Stop Exogenous Allergic Alveolitis (EAA) in Childhood Placebo, Prednisolone - Hypersensitivity Pneumonitis, Exogenous Allergic Alveolitis | Phase 2 | Terminated | Matthias Griese | 4 | 2015-04-01 | 2024-12-18 |
| European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis | Recruiting | Matthias Griese | 1000 | 2013-12-01 | 2022-09-21 |
Lung Diseases, Interstitial (2) · Alveolitis, Extrinsic Allergic (1) · Pulmonary Alveolar Proteinosis (1) · Pulmonary Eosinophilia (1) · Pulmonary Fibrosis (1) · Respiratory Distress Syndrome, Newborn (1)
Hydroxychloroquine (1) · Methylprednisolone (1) · Prednisolone (1)
Germany (3) · Turkey (Türkiye) (1) · United Kingdom (1)
Meike Hengst, MD (1)